This initial independent research project will focus on the structure/function relationships in CCR5 and related HIV-1 and SIV co-receptors. The entry of HIV and SIV into CD4+ target cells is initiated by the binding of the viral envelope glycoproteins to cell surface CD4. We and others have demonstrated that chemokine receptors then mediate essential transitory steps leading to viral-to-cell membrane fusion. The CCR5 molecule is the principle co-receptor for M-tropic HIV-1 strains that are most commonly transmitted between individuals. However, the determinants of CCR5 interactions with the HIV-1 envelope glycoproteins remain largely unknown.
In Specific Aim 1, we will continue to identify residues in the extracellular loops of CCR5 that are important for HIV-1 and SIV co-receptor activity. Several biological assays will be used to elucidate the role of functionally relevant residues in viral fusion.
In Specific Aim 2, we will determine if the functional domains of different HIV-1 and SIV co-receptors share a common structure.
In Specific Aim 3, we will determine the binding sites of new anti-CCR5 MAbs and pharmacological agents that inhibit CCR5-mediated fusion and entry. We will then map the extracellular surface of CCR5 by a MAb cross-competition analysis. Together, these studies will identify the elements in CCR5 and related co-receptors that are important for viral fusion and entry, and characterize their spatial distribution on the CCR5 surface. The studies of the targets on CCR5 for MAbs and low molecular weight compounds will facilitate the development of inhibitors of co-receptor function. Our investigations will provide a detailed molecular picture of an essential step in the HIV-1 life cycle, and ways to inhibit it by antiviral agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI043847-01
Application #
2718276
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1998-06-15
Project End
2001-05-31
Budget Start
1998-06-15
Budget End
1999-05-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Aaron Diamond AIDS Research Center
Department
Type
DUNS #
786658872
City
New York
State
NY
Country
United States
Zip Code
10016
Safarian, Diana; Carnec, Xavier; Tsamis, Fotini et al. (2006) An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. Virology 352:477-84
Seibert, Christoph; Ying, Weiwen; Gavrilov, Svetlana et al. (2006) Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349:41-54
Carnec, Xavier; Quan, Lan; Olson, William C et al. (2005) Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1. J Virol 79:1930-3
Tsamis, Fotini; Gavrilov, Svetlana; Kajumo, Francis et al. (2003) Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 77:5201-8
Thompson, Daniah A D; Cormier, Emmanuel G; Dragic, Tatjana (2002) CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus type 1 primary isolates. J Virol 76:3059-64
Cormier, Emmanuel G; Dragic, Tatjana (2002) The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol 76:8953-7
Cormier, E G; Tran, D N; Yukhayeva, L et al. (2001) Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol 75:5541-9
Nagashima, K A; Thompson, D A; Rosenfield, S I et al. (2001) Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 183:1121-5
Dragic, T; Trkola, A; Thompson, D A et al. (2000) A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A 97:5639-44
Cormier, E G; Persuh, M; Thompson, D A et al. (2000) Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A 97:5762-7

Showing the most recent 10 out of 13 publications